EX-99.2 3 neonctechnologies_ex99-2.htm EXHIBIT 99.2

Exhibit 99.2

Significant Radiographic Response and Long - Term Survival in Recurrent WHO Grade 3/4 IDH1 - mutant Astrocytoma Treated with Intranasal NEO100 Amir Heshmatpour , Executive Chairman, President & CEO Dr. Thomas C Chen, Chief Medical Officer Dr. Josh Neman, Chief Clinical Officer Dr. Henry Friedman, Chair of NTHI SAB Dr. Alex Miller, Member of NTHI SAB November 12, 2025 NEO100 is a patented Investigational New Drug (IND) patented to NeOnc Technologies Holdings Inc. (Nasdaq: NTHI) Version of October 5, 2025

Meeting Agenda • Introductions – Amir Heshmatpour • Purpose of Meeting – Dr. Thomas Chen • NEO100 - 1 Phase 2a update – Dr. Josh Neman • NEO100 Radiographic Response - Dr. Thomas Chen • Long Term Survivors – Dr. Josh Neman and Dr. Thomas Chen • Discussion – Drs. Henry Friedman, Alex Miller • Q&A and Closing Remarks - Amir Heshmatpour

Phase 2 Development & Clinical Pipeline 3 FDA Authorized Clinical Trials Commercialization Phase III Phase II Phase I IND Enabling * Preclinical Indication Application Drug Candidate Recurrent Grade III & Grade IV Astrocytoma Brain Cancer w/ IDH1 Mutation Intranasal NEO100 - 01 Meningioma Brain Tumors Intranasal NEO100 - 02 All Brain Tumors Oral NEO212 Pediatric Brain Tumors Intranasal NEO100 & Combined with Chemotherapy NEO100 - 03 Pediatric Application * NEO212 Received Phase 2 Approval **IND Enabling: Research to establish whether a compound is reasonably safe for initial use in humans and exhibits pharmacolo gic al activity that justifies commercial development. Phase 1 * Phase 1** Our Clinical Pipeline Continues to Expand to Include Other Applications of NEO100 & NEO212 Important Disclaimer: This development & clinical pipeline is subject to regulatory approval, risk and uncertainties, as well as potential changes to the pipeline and other factors that are beyond our control. Phase 2 Phase 2a 7 of 30 13 of 15 Last Cohort Completed 25 of 25 0 of 6 Maximum Tolerated Dosage not reached

NEO100 - 1 Phase 2a Objectives Eligibility Requirements: • Patients with WHO recurrent isocitrate dehydrogenase - 1 (IDH1) – mutant Grade 3/4 Astrocytoma Primary Objective ● Determine Progression - Free Survival at 6 months (PFS - 6). Secondary Objectives ● Assess Objective Response Rate (ORR) by RANO criteria. ● Determine Overall Survival (OS) and median PFS. ● Evaluate potential safety/tolerability of intranasal NEO100 at the MTD (1152 mg/day). ● Confirm systemic exposure via perillic acid levels. ● Collect preliminary Quality - of - Life (EORTC QLQ - C30 and BN - 20) data. ● Conduct subgroup analyses: IDH1 - mutant Grade IV glioma vs Grade III astrocytoma.

NEO100 - 01 Phase 2a: 6 - Month Progression Free Survival Historical IDH1 mut recurrent HGG 1,2 NEO100 - 01 Metric 21 - 31% 44% (8/18) 6 months Progression Free Survival References: 1 Fanucci et al., 2023 2 Walbert et al. 2010 ≥6 - month follow - up prior to data cutoff.

Significant Radiographic Response and Long Term Survivor Cohort Summary Patients with recurrent isocitrate dehydrogenase - 1 (IDH1) – mutant WHO Grade 3/4 Astrocytoma A total of 24 patients received intranasal NEO100 across Phase 1 (n=5) and Phase 2a (n=18) clinical trials, as well as one compassionate use case (n=1). All patients were enrolled in the study for a minimum of six months prior to data cutoff. MRI - confirmed Radiographic Response (Contrast, Perfusion) No major toxicity reported and chronic intranasal dosing.

NEO100 - 1 Radiographic Response Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO Diagnosis Age as of 10/4/2025 Sex Study Phase Patient ID Y, 8.38 4.83 Y 58 6/4/18 6/16/2017 Both Astrocytoma, IDH - Mutant (Grade IV) 46 years 6 months 10 days F 1 01 - 301 Cleveland Clinic N, 1.59 0.58 Y 7 4/9/2025 05/08/2024 Radiographic Response Astrocytoma, IDH - Mutant (Grade IV) 34 years 9 months 19 days M 2a 01 - 514 Cleveland Clinic N, 2.46 1.0 Y 12 10/24/2024 5/18/2023 Radiographic Response Astrocytoma, IDH - Mutant (Grade IV) 32 years 5 months 27 days F 2a 10 - 501 Augusta/G A Cancer Center Y, 7.05 0.63 Y 7 3/20/2025 10/18/2018 Radiographic Response Astrocytoma, IDH - Mutant (Grade IV) 30 years 11 months 7 days F 2a 11 - 502 Atlantic Health N,3.75 2.69 Y 34 2/27/23 2/3/2022 Radiographic Response Astrocytoma, IDH - Mutant (Grade IV) 63 years F 1 compassi onate patient APR_SPEI ND

• Diagnosis: WHO Grade IV IDH1 - mutant Astrocytoma , MGMT - unmethylated • Presentation: Seizure on 01 Feb 2022 → MRI showed new partially necrotic left parietal mass (5.7 î 3.4 î 4.6 cm) with nodular enhancement and intratumoral hemorrhage involving the splenium of the corpus callosum with mild contralateral extension. • Surgery: Gross total resection (03 Feb 2022) • Adjuvant Therapy: Concurrent radiation + temozolomide , followed by 6 cycles of maintenance temozolomide (final cycle began Oct 2022 ) • Post - treatment MRI (20 Oct 2022): Postsurgical changes with increased nodular enhancement (14.5 mm, previously 8 mm) along the anterior aspect of the resection cavity; no new lesions. • Follow - up: • PET (12 Dec 2022) confirmed metabolic activity consistent with recurrence. • No active therapy after Oct 2022; awaiting insurance approval for lomustine as backup option. • MRI (26 Jan 2023): Interval increase in size and irregularity of left periventricular enhancing mass (4.6 cm) prior to initiating NEO100 . • Other Therapy: No other anti - tumor treatment received while on NEO100 study Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO Diagnosis Age as of 10/4/2025 Sex Study Phase Patient ID N,3.75 2.69 Y 34 2/27/23 2/3/2022 Radiographic Response Astrocytoma, IDH - Mutant (Grade IV) 63 years F 1 compassi onate patient APR_SPEI ND

Cycle 8 1.1 AP x 1.5 TR cm Cycle 34 .31 AP x .71 TR cm Baseline (Pre - NEO100) ~ 4.7cm Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO Diagnosis Age as of 10/4/2025 Sex Study Phase Patient ID N,3.75 2.69 Y 34 2/27/23 2/3/2022 Radiographic Response Astrocytoma, IDH - Mutant (Grade IV) 63 years F 1 compassio nate patient APR_SPEIN D Post contrast Post contrast Perfusion: rCBV Post contrast

• Diagnosis: WHO Grade IV IDH1 - mutant Astrocytoma, MGMT status unknown • Initial Management: Surgical resection on 16 Jun 2017 • Adjuvant Therapy: – Radiation therapy: 24 Aug 2017 – 05 Oct 2017 – Temozolomide (4 cycles): 24 Nov 2017 – 22 Apr 2018 – Optune device: Used concurrently with temozolomide only • Pre - study MRI: 25 May 2018 — performed post – adjuvant therapy, showing evidence of relapse or progression • Clinical Trial Enrollment: Initiated NEO100 study; first dose administered 04 Jun 2018 • Additional Therapy: No other anti - tumor treatment received while on NEO100 study Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO Diagnosis Age as of 10/4/2025 Sex Study Phase Patient ID Y, 8.38 4.83 Y 58 6/4/18 6/16/2017 Both Astrocytoma, IDH - Mutant (Grade IV) 46 years 6 months 10 days F 1 01 - 301 Cleveland Clinic

Baseline (Pre - NEO100) 0.63 AP x 1.39 TR cm Cycle 2 0.64 AP x 1.55 TR cm Cycle 57 0 AP x 0 TR cm Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO diagnosis Age as of 10/4/2025 Sex Study Phase Patient ID Y, 8.38 4.83 Y 58 6/4/18 6/16/2017 Both Astrocytoma, IDH - Mutant (Grade IV) 46 years 6 months 10 days F 1 01 - 301 Cleveland Clinic Post contrast Post contrast Perfusion: rCBV Post contrast Perfusion: rCBV

• Diagnosis: WHO Grade IV IDH1 - mutant Astrocytoma, MGMT status unknown • Initial Management: Biopsy on 18 May 2023, followed by resection on 27 Jun 2023 • Adjuvant Therapy: – Radiation therapy: 31 Jul 2023 – 20 Sep 2023 – Temozolomide (1 cycle): 31 Jul 2023 – 07 Aug 2023 • Subsequent Therapy (after progression): Lomustine (2 cycles): 08 Apr 2024 – 18 Jul 2024 • Pre - study MRI: 19 Oct 2024 • Clinical Trial Enrollment: Began NEO100 study; first dose administered 24 Oct 2024 • Additional Therapy: No other anti - tumor treatment received while on NEO100 study Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO Diagnosis Age as of 10/4/2025 Sex Study Phase Patient ID N, 2.46 1.0 Y 12 10/24/2024 5/18/2023 Radiographic Response Astrocytoma, IDH - Mutant (Grade IV) 32 years 5 months 27 days F 2a 10 - 501 Augusta/GA Cancer Center

Baseline (Pre - NEO100) . 49 AP x .60 TR cm Cycle 2 .52 AP x .52 TR cm Cycle 12 0 AP x 0 TR Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO diagnosis Age as of 10/4/2025 Sex Study Phase Patient ID N, 2.46 1.0 Y 12 10/24/2024 5/18/2023 Radiographic Response Astrocytoma, IDH - Mutant (Grade IV) 32 years 5 months 27 days F 2a 10 - 501 Augusta/G A Cancer Center Post contrast Post contrast Post contrast Perfusion: rCBV

• Diagnosis: WHO Grade IV IDH1 - mutant Astrocytoma , MGMT status unknown • Initial Management: Surgical resection on 12 Oct 2018 → pathologic diagnosis confirmed 18 Oct 2018 • Adjuvant Therapy: Radiation therapy + Temozolomide , 13 Feb 2019 – 16 May 2019 • Screening MRI: 06 Mar 2025 • Clinical Trial Enrollment: Began NEO100 study; first dose administered 20 Mar 2025 • Additional Therapy: No other anti - tumor treatment received while on NEO100 study Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO Diagnosis Age as of 10/4/2025 Sex Study Phase Patient ID Y, 7.05 0.63 Y 7 3/20/2025 10/18/2018 Radiographic Response Astrocytoma, IDH - Mutant (Grade IV) 30 years 11 months 7 days F 2a 11 - 502 Atlantic Health

Baseline (Pre - NEO100) 1.42 AP x 1.37 TR cm Cycle 2 1.00 AP x 1.23 TR cm Cycle 7 1.67 AP x 1.37 TR cm Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO diagnosis Age as of 10/4/2025 Sex Study Phase Patient ID Y, 7.05 0.63 Y 7 3/20/2025 10/18/2018 Radiographic Response Astrocytoma, IDH - Mutant (Grade IV) 30 years 11 months 7 days F 2a 11 - 502 Atlantic Health Post contrast Perfusion: rCBV Post contrast Perfusion: rCBV Post contrast

• Diagnosis: WHO Grade IV IDH1 - mutant Astrocytoma , MGMT - unmethylated , • Initial Management: Underwent surgical resection on 08 May 2024 • Adjuvant Therapy: • Radiation therapy: 24 Jun 2024 – 05 Aug 2024 • Temozolomide: 02 Sep 2024 – 13 Jan 2025 • Screening MRI: 31 Mar 2025 • Clinical Trial Enrollment: Initiated NEO100 study; first dose administered on 09 Apr 2025 • Other Therapy: No other anti - tumor treatment received while on NEO100 study Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO Diagnosis Age as of 10/4/2025 Sex Study Phase Patient ID N, 1.59 0.58 Y 7 4/9/2025 05/08/2024 Radiographic Response Astrocytoma, IDH - Mutant (Grade IV) 34 years 9 months 19 days M 2a 01 - 514 Cleveland Clinic

Baseline (Pre - NEO100) . 73 AP x .35 TR cm Cycle 2 .58 AP x .36 TR cm Cycle 6 .58 AP x .75 TR cm Long Term Survival (Y/N) Time on NEO100 (years) Alive Cycles Completed C1D1 Date Primary Diagnosis Date long term survivor, radiographic response, both WHO Diagnosis Age as of 10/4/2025 Sex Study Phase Patient ID N, 1.59 0.58 Y 7 4/9/2025 05/08/2024 Radiographic Response Astrocytoma, IDH - Mutant (Grade IV) 34 years 9 months 19 days M 2a 01 - 514 Cleveland Clinic Post contrast Perfusion: rCBV Post contrast Perfusion: rCBV Post contrast Perfusion: rCBV

Long - Term Survival: Recurrent WHO Grade 3/4 IDH1 - mutant Astrocytoma • No major toxicity reported across cohort; chronic intranasal dosing well tolerated • Adverse events predominantly low - grade; safety consistent with prolonged exposure + Subject alive 8 of 24 patients are long - term survivors, surviving ≥18 months following initiation of NEO100, with a median overall survival of 88 months

Summary: NEO100 - 01 Clinical Outcomes for Recurrent WHO Grade 3/4 IDH1 - mutant Astrocytoma Progression - Free Survival: 44% of patients achieved 6 - month progression - free survival (PFS - 6), outperforming historical benchmarks of 21 – 31% for IDH1 - mutant recurrent high - grade gliomas. Radiographic Response: 21% of patients achieved significant radiographic remission. This response rate exceeds the <8% typically observed with salvage therapies for recurrent gliomas. Long - Term Survival: 33% of patients demonstrated durable survival ≥18 months post - initiation of NEO100 with median overall survival of 88 months.

Impact & Significance • First - of - its - kind signal for durable response: MRI - confirmed significant response in setting rarely seen • Potential paradigm shift with multi - year survival: CNS - penetrant metabolic therapy • Differentiation: Minimal toxicity vs. standard salvage therapies • Translational momentum: Supports Phase 2b/3 and global trials (e.g., Cleveland Clinic, UAE, M42/IROS)

Significant Radiographic Response and Long - Term Survival in Recurrent WHO Grade 3/4 IDH1 - mutant Astrocytoma Treated with Intranasal NEO100 Discussion – Drs. Henry Friedman, Alex Miller Q&A NEO100 is a patented Investigational New Drug (IND) patented to NeOnc Technologies Holdings Inc. (Nasdaq: NTHI) Version of October 5, 2025